Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials

DOI: 10.1080/2162402X.2017.1396403

Keywords: anti-PD-1, atezolizumab, immunotherapy, nivolumab, non-small cell lung cancer, pembrolizumab

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text